Peptitech
About
Areas of activity
Health
Additional information
Establishment year
2019
Organization description
Peptitech is a preclinical-stage biopharmaceutical company founded in 2029 and headquartered in Milan, Italy. It operates as an independent legal entity with a proprietary patent portfolio protecting its compounds and mechanisms of action. The company maintains a lean organizational structure and collaborates with a network of scientific and industrial partners to support its development activities.
Business Project Description
Glutamate excitotoxicity drives neurodegeneration in glaucoma. Current therapies only lower eye pressure. Peptitech's GN-01GRi is a first-in-class eye-drop peptide selectively inhibiting presynaptic NMDA receptors, reducing toxic glutamate without blocking neurotransmission. Target: glaucoma, retinal diseases, Alzheimer's/Parkinson's. Model: out-licensing, co-development. Team: neuroscience, pharmacology, business. Funds will complete preclinical development, IND-enabling studies, regulatory prep.
Product/Technology Development Stage
Proof of concept
Team size
1-2
Team Background
IPR Status
Type of funding raised
Annual turnover (€)
100 - 500k
I participated in the Start Cup initiative of Lombardy Region
Yes
I received the Seal of Excellence for an EIC Accelerator project proposal
No
Representatives
Professor Pharmacology
Peptitech